Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) Research & Development: 2013-2025

Historic Research & Development for MediWound (MDWD) over the last 13 years, with Sep 2025 value amounting to $3.5 million.

  • MediWound's Research & Development rose 37.28% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year increase of 66.60%. This contributed to the annual value of $8.9 million for FY2024, which is 18.90% up from last year.
  • According to the latest figures from Q3 2025, MediWound's Research & Development is $3.5 million, which was down 0.74% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, MediWound's Research & Development peaked at $3.5 million during Q2 2025, and registered a low of $1.5 million during Q1 2024.
  • For the 3-year period, MediWound's Research & Development averaged around $2.4 million, with its median value being $2.1 million (2023).
  • Per our database at Business Quant, MediWound's Research & Development crashed by 46.83% in 2023 and then surged by 96.33% in 2025.
  • Quarterly analysis of 5 years shows MediWound's Research & Development stood at $2.5 million in 2021, then increased by 9.67% to $2.7 million in 2022, then plummeted by 33.01% to $1.8 million in 2023, then spiked by 65.15% to $3.0 million in 2024, then surged by 37.28% to $3.5 million in 2025.
  • Its Research & Development stands at $3.5 million for Q3 2025, versus $3.5 million for Q2 2025 and $2.9 million for Q1 2025.